Catherine M. Engelbert
Catherine M. Engelbert's purchase track record
Catherine M. Engelbert has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/3/2023 | MCD | $11K | +5.1% | -7.7% | +4.0% |
| 2/28/2022 | MCD | $244K | +3.0% | +5.0% | -7.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
McDonald's Dividend Raise Seen as Fair Value Signal. McDonald's recently raised its dividend, with analysts suggesting the stock may now be trading near fair value. While the company offers a yield above 3%, recent coverage highlights a lack of strong growth catalysts beyond the payout. The stock currently sits within a wide 52-week range, reflecting mixed sentiment on its future performance.
Transaction History
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 7,614 | $0 | 5/13/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 9,293 | $0 | 6/7/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 7,747 | $0 | 6/23/2023 | View on chart |
| MCD | ▲ Buy | Open Market | 38 | $11K | 4/3/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 6,328 | $0 | 6/24/2022 | View on chart |
| MCD | ▲ Buy | Open Market | 1,000 | $244K | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.